The sustainable development of the national economy depends on the continuous growth and growth of the capital market, and the stock market is an important factor of the capital market. The growth of the stock market can generate a huge positive force for the country's economic strength, and the steady growth of the stock market also plays a pivotal role in the overall economic pulsation and is very helpful to the country's high economic development. There are different views on whether the technical analysis of the stock market is efficient. This study aims to explore the feasibility and efficiency of using deep network and technical analysis indicators to estimate short-term price movements of stocks. The subject of this study is TWSE 0050, which is the most traded ETF in Taiwan's stock exchange, and the experimental transaction range is 2017/01 ~ 2019 Q3. A four layer Long Short-Term Memory (LSTM) model was constructed. This research uses well-known technical indicators such as the KD, RSI, BIAS, Williams% R, and MACD, combined with the opening price, closing price, daily high and low prices, etc., to predict the trend of stock prices. The results show that the combination of technical indicators and the LSTM deep network model can achieve 83.6% accuracy in the three categories of rise, fall, and flatness.

Background and objective: BRCA1 and BRCA2 are associated with many cancer types in addition to hereditary breast and ovarian cancers. However, their relation to lung cancer remains to be explored. Materials and Methods: Observation studies were systematically reviewed to explore the association of BRCA1 or BRCA2 with lung cancer. PubMed, MEDLINE [EBSCOhost], and relevant articles published up to 7 January 2020 were searched. Odd ratio (OR), standardized morbidity rate (SMR), and cancer-specific standardized incidence ratios (SIRs) were pooled together as relative risk (RR) estimates (95% confidence interval [CI], 0.66–1.40). Results: Thirteen studies were included for analysis. Results showed that the RR of BRCA2 is 0.76 (95% CI, 0.48–1.19), the overall RR is 0.96 (95% CI, 0.66–1.40), and that of BRCA1 is 0.66 (95% CI, 0.41–1.05), indicating that it was not associated with lung cancer. Conclusion: With the limitation of the retrospective study design and severe heterogeneity, these results inform clinicians and relevant families that BRCA1 and BRCA2 mutation carriers have no increased risk of lung cancer.